Tag: Jounce
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021...
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature-...
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common...
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and...